Syndax Pharmaceuticals to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

December 04, 2023 | Last Trade: US$9.01 0.36 -3.84

WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65^th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:

Daniel Wolff, M.D., Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
Eytan M. Stein, M.D., Chief, Program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center
Ghayas C. Issa, M.D., Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Joshua F. Zeidner, M.D., Associate Professor of Medicine, Chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center
Neerav N. Shukla, M.D., Chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website or directly through the meeting link here.

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel 781.684.9827

Stock Quote

Last Trade:	US$9.01
Daily Change:	-0.36 -3.84
Daily Volume:	196,773
Market Cap:	US$769.090M

June 24, 2025 Syndax Pharmaceuticals Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia June 12, 2025 Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 June 12, 2025 Syndax Pharmaceuticals Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 May 14, 2025 Syndax Pharmaceuticals Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) May 07, 2025 Syndax Pharmaceuticals Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood LOAD MORE NEWS

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE